Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q1 EPS of ($0.79), $0.49 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.75 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.